Not yet recruitingInterventionalPhase 1Phase 2Last updated Aug 12, 2026

Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma

Phase Ib/II Study to Evaluate the Safety, Tolerability and Efficacy of Combination Therapy With SYS6090 Injection in Participants With Hepatocellular Carcinoma

Overview

ClinicalTrials.gov ID: NCT07761286
Lead Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY
Brief Summary: This is an open-label, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of combination therapy with SYS6090 Injection in participants with hepatocellular carcinoma (HCC).
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Sep 30, 2026Estimated
Primary Completion Date: Sep 30, 2029Estimated
Completion Date: Sep 30, 2031Estimated

Study Record Dates

First Submitted: Jul 30, 2026
First Submitted that Met QC Criteria: Aug 7, 2026
First Posted: Aug 12, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 7, 2026
Last Update Posted: Aug 12, 2026Actual
Last Verified: Jul 2026

NCT05444088Unknown status

Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma

NCT01308645Unknown status

Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma (HCC)

NCT07478302Recruiting

A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma

NCT04605796Completed

A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

NCT05363722Unknown status

A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma

NCT07490262Recruiting

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.